Andere talen Lumos Pharma, Inc.

Aandelen

LUMO

US55028X1090

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,8 ^USD	+4,48%		+11,11%	-11,95%

07/03	Lumos Pharma, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
07/03	Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings	18/04
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042	20/03
Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Earnings Flash (LUMO) LUMOS PHARMA Reports Q4 Revenue $2.1M	07/03
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update	07/03
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	26/02
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	26/02
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	05/02
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	05/02
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer	04/01
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer	04/01
Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer	04/01
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency	21/11
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency	21/11
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November	20/11
North American Morning Briefing : Stock Futures -2-	13/11
Top Premarket Gainers	08/11
Lumos Pharma Phase 2 Trials Targeting Pediatric Growth Hormone Deficiency Meet Endpoints; Shares Surge Premarket	08/11
Lumos: Q3 Earnings Snapshot	08/11
Lumos Pharma Shares Than Double After Hormone Deficiency Trial Meets All Endpoints	08/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Lumos Pharma, Inc.

Aandelen

LUMO

US55028X1090

Andere talen

Filters